Could a vaccine shield HIV-Exposed newborns? early trial launches
NCT ID NCT06613789
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial will test a new HIV vaccine in 22 infants who were exposed to HIV during birth but are not infected. The vaccine is designed to train the immune system to recognize and fight HIV. The main goal is to see if the vaccine is safe and whether it triggers an immune response. The study is not yet recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
426c.Mod.Core-C4b vaccine with 3M-052-AF and alum adjuvants
What this could lead to
If successful, this could point toward a safe vaccine to protect HIV-exposed infants from infection.
What could go wrong
This is a very early Phase 1 trial with only 22 infants, so it is primarily checking safety, not effectiveness. The vaccine may not produce a strong immune response or could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Soweto HVTN CRS
Soweto, Gauteng, 1862, South Africa
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••